Preventing the danger of unwanted CAR expression during lentivirus production
Join this exclusive webinar to discover advanced strategies for enhancing the quality of lentiviral (LV) vectors in cell therapy manufacturing.
Quality defects in LV vectors can significantly affect the efficacy and safety of final cell therapies. Despite their critical importance, there has been minimal focus on controlling and monitoring the quality of LV vectors used in cell therapy manufacture. Of particular concern is the risk of ‘breakthrough expression’ of the transgene, leading to CAR expression in producer cells and on the surface of the LV particle.
In this webinar, Lentitek will demonstrate how its promoter system is designed to significantly reduce breakthrough expression of the transgene in producer cells, maximizing the functional LV titer during anti-CD19 CAR vector production. Additionally, the webinar will showcase the Leprechaun platform from Unchained Labs, which promises precise identification and monitoring of CAR expression on the LV surface. This webinar is essential for professionals dedicated to improving quality and safety of cell therapies.
Key takeaways include:
- Preventing breakthrough expression: Comprehend why preventing breakthrough transgene expression is critical for the safety and efficacy of your cell therapy.
- Optimizing LV performance: Understand how Lentitek’s system can help prevent unwanted transgene expression.
- Comprehensive quality monitoring: Learn how Leprechaun helps you monitor breakthrough expression by measuring the titer of LV with transgene protein on the surface straight from harvest.
Who should attend?
- Senior scientists, professors, and postdoctoral researchers working in lentiviral process and analytical development.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Speakers
Dr. Alex Shephard is the Market Manager for cell therapy at Unchained Labs. She has many years of experience at the bench and as a field application scientist characterizing exosomes and viruses, using techniques including NTA, DLS, nanoflow cytometry, fluorescence microscopy, and interferometry. Alex completed a Ph.D. in Molecular Biology at Bristol University, UK, and held a postdoc position in the Tumour Microenvironment Group at Cardiff University, UK.
A scientist by trade, Adam has a Ph.D. in cancer biology from Oxford University and an executive MBA from Edinburgh. After a decade in R&D at AstraZeneca, Applied Biosystems, and Lab901, Adam has spent the last 15 years in marketing and commercial roles developing market and product strategy for the likes of Agilent, Merck-BioReliance, and Symbiosis.
Moderator
